Tag: CSE:RAMM
July 16, 2020
RAMM Pharma Announces Approval and Registration of Epifractán™ 2 Percent by Peru’s Ministry of Health
RAMM Pharma is pleased to announce that the Company’s Epifractán™ 2% formulation has been approved and registered by Peru’s Ministry...
July 9, 2020
RAMM Pharma Announces Approval and Registration of Epifractán™ 5 Percent by Peru’s Ministry of Health and Enters Distribution Agreement to Supply Pharmacies in Peru
RAMM Pharma Corp. is pleased to announce that the Company’s Epifractán™ 5% formulation has been approved and registered by Peru’s...
April 15, 2020
RAMM Pharma Corp. Announces Intention to Commence Normal Course Issuer Bid
RAMM Pharma Corp. (CSE:RAMM)announces its intention to commence a normal course issuer bid, under which it may purchase up to...
March 30, 2020
RAMM Pharma Corp. Announces Postponement of Filing of Interim Financial Statements
RAMM Pharma announces that it will not be filing its interim financial statements for the quarter ended January 31, 2020.
March 26, 2020
RAMM Pharma Corp. Receives Federal Approval and Registration of XALEX™ 10 (cannabidiol) Oral Solution
RAMM Pharma (CSE:RAMM)is pleased to announce that the Uruguayan Ministry of Public Health has approved and registered XALEX™ 10 (cannabidiol)...
March 23, 2020
RAMM Pharma Corp. Provides Details on Operational Activities to Support COVID-19 Medical Response Effort & Corporate Update
RAMM Pharma Corp. (CSE: RAMM) provided a corporate update and information regarding the Company’s ongoing support of the medical community’s...
February 25, 2020